Boston Scientific Corporation (BSX) Releases Earnings Results, Reports EPS of $0.27 EPS

Boston Scientific Corporation (BSX) reported quarterly earnings results on Thursday, Jul-28-2016. The company reported $0.27 EPS for the quarter. Analysts had a consensus estimate of $0.27. The company posted revenue of $2126.00 million in the period, compared to analysts expectations of $2044.88 million. The company’s revenue was up 15.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS.

Many Wall Street Analysts have commented on Boston Scientific Corporation. Boston Scientific Corporation was Initiated by Guggenheim to “Buy” on Jun 9, 2016.

Boston Scientific Corporation opened for trading at $24.44 and hit $24.79 on the upside on Thursday, eventually ending the session at $24.34, with a gain of 2.87% or 0.68 points. The heightened volatility saw the trading volume jump to 2,42,80,806 shares. Company has a market cap of $33,026 M.

In a different news, on Jul 20, 2016, David A Pierce (SVP and President, Endoscopy) sold 2,480 shares at $24.03 per share price. According to the SEC, on Jul 20, 2016, Michael P. Phalen (EVP & President, MedSurg) sold 35,000 shares at $24.03 per share price. On Jul 5, 2016, Timothy A. Pratt (EVP, GC & Chief Admin Officer) sold 24,000 shares at $23.39 per share price, according to the Form-4 filing with the securities and exchange commission.

Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Women’s Health and Neuromodulation.

Boston Scientific Corporation

Leave a Reply

Boston Scientific Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Boston Scientific Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.